India's Cipla to make and sell Eli Lilly's baricitinib to treat COVID-19

BENGALURU (Reuters) -Indian drugmaker Cipla Ltd said on Monday it had entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients. The agreement comes at a time when India is struggling with a catastrophic...